Richard W Groen

List of Publications by Year
in descending order

54 papers	2,841 citations	257450 24 h-index	233421 45 g-index
56 all docs	56 docs citations	56 times ranked	4466 citing authors

#	Article	IF	Citations
1	Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells. IScience, 2022, 25, 103605.	4.1	6
2	Time 2EVOLVE: predicting efficacy of engineered T-cells â€" how far is the bench from the bedside?. , 2022, 10, e003487.		13
3	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. Clinical Cancer Research, 2021, 27, 3793-3803.	7.0	27
4	SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia. Leukemia, 2021, 35, 2698-2702.	7.2	9
5	CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an â€œOff the Shelfâ€•Therapy for Multiple Myeloma. HemaSphere, 2021, 5, e596.	2.7	11
6	Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma. Blood, 2021, 138, 1612-1612.	1.4	0
7	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Science Translational Medicine, 2021, 13, eabh1962.	12.4	49
8	Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. Haematologica, 2020, 105, e80-e83.	3.5	12
9	Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone. JBMR Plus, 2020, 4, e10247.	2.7	7
10	Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma. HemaSphere, 2020, 4, e463.	2.7	5
11	Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications. Blood, 2020, 136, 40-40.	1.4	0
12	Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma. Journal of Controlled Release, 2019, 296, 232-240.	9.9	27
13	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptorâ€"engineered T Cells. Clinical Cancer Research, 2019, 25, 4014-4025.	7.0	110
14	CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, e100-e103.	3.5	90
15	The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma. Blood, 2019, 134, 137-137.	1.4	10
16	Pharmacological Perturbation of the Immunoproteasome in Hematologic Neoplasias: Therapeutic Implications. Blood, 2019, 134, 1291-1291.	1.4	2
17	Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma. Blood, 2019, 134, 4407-4407.	1.4	4
18	Functional Interactions between Transcription Factors Involved in Myeloma Pathogenesis - Biological and Therapeutic Implications. Blood, 2019, 134, 315-315.	1.4	0

#	Article	IF	Citations
19	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 2017, 25, 1946-1958.	8.2	197
20	Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models. Experimental Hematology, 2017, 51, 36-46.	0.4	19
21	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research, 2017, 23, 7498-7511.	7.0	134
22	Realgar nanoparticles <i>versus </i><scp>ATO</scp> arsenic compounds induce <i>inÂvitro</i> and <i>inÂvivo</i> activity <i>against</i> multiple myeloma. British Journal of Haematology, 2017, 179, 756-771.	2.5	26
23	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica, 2016, 101, 616-625.	3.5	136
24	The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via FcÎ³ Receptorâ€"Mediated Cross-Linking. Journal of Immunology, 2016, 197, 807-813.	0.8	225
25	Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis. Cell Reports, 2016, 14, 332-346.	6.4	126
26	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs, 2015, 7, 311-320.	5.2	405
27	Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia, 2015, 29, 2039-2049.	7.2	217
28	Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunology, Immunotherapy, 2015, 64, 951-963.	4.2	47
29	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clinical Cancer Research, 2015, 21, 2802-2810.	7.0	136
30	Addition of the Vascular Niche Component to the Human Bone Marrow-like Scaffold Model. Blood, 2015, 126, 2402-2402.	1.4	0
31	Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease. Clinical Cancer Research, 2014, 20, 1542-1554.	7.0	75
32	Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 2014, 124, 644-655.	8.2	180
33	Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All-Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab. Blood, 2014, 124, 2096-2096.	1.4	3
34	CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma. Blood, 2014, 124, 4759-4759.	1.4	8
35	Evaluation of Extrinsic and Intrinsic Cues Involved in BCR-ABL-Induced Leukemogenesis. Blood, 2014, 124, 515-515.	1.4	0
36	Establishing Human Niche Xenograft Models for Myeloid and Lymphoid Leukemia Driven By MLL-AF9. Blood, 2014, 124, 4781-4781.	1.4	0

#	Article	IF	Citations
37	Decoding the Pathophysiology and the Genetics of Multiple Myeloma to Identify New Therapeutic Targets. Seminars in Oncology, 2013, 40, 537-548.	2.2	9
38	Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance. Clinical Cancer Research, 2013, 19, 5591-5601.	7.0	48
39	Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells. Clinical Cancer Research, 2013, 19, 1467-1475.	7.0	27
40	Establishing Human Niche Xenograft Models For Myeloid and Lymphoid Leukemia Driven By MLL-AF9. Blood, 2013, 122, 1646-1646.	1.4	1
41	CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients. Blood, 2013, 122, 277-277.	1.4	4
42	Mouse Versus Human Extrinsic Cues Dictate Transformation Potential In BCR-ABL/BMI1-Induced Leukemia In Humanized Xenograft Models. Blood, 2013, 122, 515-515.	1.4	29
43	Disregulated Osteogenesis By Mesenchymal Stromal Cells (MSC) After In Vivo Exposure To Multiple Myeloma: Studies In a Novel Humanized Mouse Model For Bone Remodelling In Myeloma. Blood, 2013, 122, 1906-1906.	1.4	0
44	Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma. PLoS ONE, 2012, 7, e30359.	2.5	41
45	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Management and Research, 2012, 4, 253.	1.9	28
46	Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood, 2012, 120, e9-e16.	1.4	104
47	Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood, 2010, 115, 601-604.	1.4	50
48	Eradication of Medullary Multiple Myeloma by CD4+ Cytotoxic Human T Lymphocytes Directed at a Single Minor Histocompatibility Antigen. Clinical Cancer Research, 2010, 16, 5481-5488.	7.0	24
49	Targeting EXT-1 Reveals a Crucial Role of Heparan Sulfate in the Growth of Multiple Myeloma.. Blood, 2009, 114, 1830-1830.	1.4	1
50	Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4 + Cytotoxic T Cells.. Blood, 2009, 114, 1333-1333.	1.4	1
51	The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment.. Blood, 2009, 114, 1847-1847.	1.4	0
52	Illegitimate WNT Pathway Activation by Î²-Catenin Mutation or Autocrine Stimulation in T-Cell Malignancies. Cancer Research, 2008, 68, 6969-6977.	0.9	41
53	A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica, 2008, 93, 1049-1057.	3.5	37
54	Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood, 2006, 107, 760-768.	1.4	80